|Day Low/High||170.96 / 176.59|
|52 Wk Low/High||114.27 / 202.22|
But don't throw up your arms yet -- here are names that could be golden opportunities.
Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.
China-based Alibaba reports quarterly performance Thursday morning. While one might think that an e-commerce type operation could do well in a quarantined environment, it's not quite that easy.
AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.
ABBV could bounce today but there remains the risk of a deeper correction.
These companies all could be strong -- even if the 2019 nCoV fear spreads.
Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.
As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year.
It seemed to happen overnight. People watched. People listened. People cared. About what? Individual stocks.
Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
These stocks are priced for total imperfection. That's just what you want.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Right now, AbbVie is the best way to capitalize on the moment and on the future.
* Only three of eleven S&P sectors are viewed as attractive * I am in a risk off state of mind. Back in 2015 I instituted a new regular feature called "Sectors," in which I periodically offered my short-term (6-12 months) price outlook for each of t...
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.
Here are my five rules for handling earnings season.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...